Barclays PLC Buys New Position in MBX Biosciences, Inc. (NYSE:MBX)

Barclays PLC purchased a new position in shares of MBX Biosciences, Inc. (NYSE:MBX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,400 shares of the company’s stock, valued at approximately $426,000.

Other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new stake in shares of MBX Biosciences during the third quarter worth $1,200,000. NEA Management Company LLC acquired a new position in MBX Biosciences during the 3rd quarter worth $93,904,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in MBX Biosciences during the 3rd quarter worth about $278,000. Maven Securities LTD acquired a new stake in MBX Biosciences in the 3rd quarter valued at about $1,299,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of MBX Biosciences in the 3rd quarter valued at about $405,000.

MBX Biosciences Stock Performance

MBX stock opened at $18.59 on Friday. MBX Biosciences, Inc. has a twelve month low of $15.31 and a twelve month high of $27.50. The business’s 50 day moving average is $20.30.

MBX Biosciences (NYSE:MBX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($2.78) EPS for the quarter, missing the consensus estimate of ($2.72) by ($0.06). As a group, analysts predict that MBX Biosciences, Inc. will post -13.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Guggenheim initiated coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They set a “buy” rating and a $44.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th. They issued a “buy” rating and a $35.00 price objective on the stock. Stifel Nicolaus began coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on MBX Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $30.00 target price on the stock.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.